CA3184633A1 - Combination therapy for treatment of myeloproliferative neoplasms - Google Patents

Combination therapy for treatment of myeloproliferative neoplasms

Info

Publication number
CA3184633A1
CA3184633A1 CA3184633A CA3184633A CA3184633A1 CA 3184633 A1 CA3184633 A1 CA 3184633A1 CA 3184633 A CA3184633 A CA 3184633A CA 3184633 A CA3184633 A CA 3184633A CA 3184633 A1 CA3184633 A1 CA 3184633A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
day
benzoxazin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3184633A
Other languages
English (en)
French (fr)
Inventor
Matthew Stubbs
Phillip C. Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CA3184633A1 publication Critical patent/CA3184633A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3184633A 2020-06-03 2020-09-14 Combination therapy for treatment of myeloproliferative neoplasms Pending CA3184633A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
US63/034,214 2020-06-03
PCT/US2020/050753 WO2021247064A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
CA3184633A1 true CA3184633A1 (en) 2021-12-09

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3184633A Pending CA3184633A1 (en) 2020-06-03 2020-09-14 Combination therapy for treatment of myeloproliferative neoplasms

Country Status (23)

Country Link
EP (2) EP4161528B1 (cg-RX-API-DMAC10.html)
JP (2) JP7669396B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230031242A (cg-RX-API-DMAC10.html)
CN (1) CN115835868A (cg-RX-API-DMAC10.html)
AU (1) AU2020451061A1 (cg-RX-API-DMAC10.html)
CA (1) CA3184633A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003409A1 (cg-RX-API-DMAC10.html)
DK (1) DK4161528T3 (cg-RX-API-DMAC10.html)
ES (1) ES3058891T3 (cg-RX-API-DMAC10.html)
FI (1) FI4161528T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251457T1 (cg-RX-API-DMAC10.html)
IL (1) IL298200A (cg-RX-API-DMAC10.html)
LT (1) LT4161528T (cg-RX-API-DMAC10.html)
MA (1) MA59868B1 (cg-RX-API-DMAC10.html)
MD (1) MD4161528T2 (cg-RX-API-DMAC10.html)
MX (1) MX2022015220A (cg-RX-API-DMAC10.html)
PH (1) PH12022553276A1 (cg-RX-API-DMAC10.html)
PL (1) PL4161528T3 (cg-RX-API-DMAC10.html)
PT (1) PT4161528T (cg-RX-API-DMAC10.html)
RS (1) RS67440B1 (cg-RX-API-DMAC10.html)
SI (1) SI4161528T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600021T1 (cg-RX-API-DMAC10.html)
WO (1) WO2021247064A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi
EP4297750A1 (en) * 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
WO2024144258A1 (ko) * 2022-12-28 2024-07-04 주식회사 삼양홀딩스 룩소리티닙의 다중 방출제어 정제 조성물 및 이의 제조 방법
EP4734995A1 (en) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Quinoline carboxamides for use in the treatment of mpn

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
SMT202000133T1 (it) * 2014-04-23 2020-05-08 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
CN109715625B (zh) 2016-06-20 2022-04-19 因赛特公司 Bet抑制剂的结晶固体形式
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Also Published As

Publication number Publication date
JP2025111539A (ja) 2025-07-30
IL298200A (en) 2023-01-01
MD4161528T2 (ro) 2026-03-31
PH12022553276A1 (en) 2024-02-19
DK4161528T3 (da) 2025-11-24
JP2023529365A (ja) 2023-07-10
CL2022003409A1 (es) 2023-05-26
PT4161528T (pt) 2026-01-23
FI4161528T3 (fi) 2025-12-12
AU2020451061A1 (en) 2022-12-15
KR20230031242A (ko) 2023-03-07
PL4161528T3 (pl) 2026-03-16
EP4161528A1 (en) 2023-04-12
RS67440B1 (sr) 2025-12-31
HRP20251457T1 (hr) 2026-01-02
SI4161528T1 (sl) 2026-01-30
WO2021247064A1 (en) 2021-12-09
MX2022015220A (es) 2023-03-08
CN115835868A (zh) 2023-03-21
EP4691563A3 (en) 2026-04-01
ES3058891T3 (en) 2026-03-13
SMT202600021T1 (it) 2026-03-09
EP4691563A2 (en) 2026-02-11
JP7669396B2 (ja) 2025-04-28
LT4161528T (lt) 2026-02-10
EP4161528B1 (en) 2025-11-05
MA59868B1 (fr) 2025-11-28

Similar Documents

Publication Publication Date Title
EP4161528B1 (en) Combination of ruxolitinib with incb057643 for use in the treatment of myeloproliferative neoplasms
US20260137695A1 (en) Combination therapy for treatment of myeloproliferative neoplasms
EP3849558B1 (en) Thiocarbamate derivatives as a2a inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
CN110913861B (zh) G1t38的形态学形式及其制造方法
CN116157403B (zh) 曲拉西利的形态及其制造方法
CN113384546A (zh) 鲁索利替尼的缓释剂型
KR20240090927A (ko) 항암 조합 요법
KR20190130644A (ko) 항암 조합 요법
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
CN119403808A (zh) 用于医学治疗的细胞周期蛋白依赖性激酶2抑制剂
KR20240016298A (ko) 재발성 원발성 cns 신생물에 대한 용도 및 방법
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
JP2024542248A (ja) Ｆｇｆｒ阻害剤とｋｒａｓ阻害剤を含む併用療法
CN113412262A (zh) 包含杂环蛋白激酶抑制剂的制剂
CN115038447A (zh) 用于治疗癌症的组合疗法
US20230165863A1 (en) Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors
KR102771163B1 (ko) 치료제의 용해도 및 생체이용률을 향상시키는 방법
HK40112852A (en) Pharmaceutical for treating or preventing cancer
TW202608439A (zh) 治療具有ａｓｘｌ１突變之個體之癌症的方法
HK40112620A (en) Novel use of quinazolinone compound for the treatment of cancer
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240905

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240905

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240906

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240906

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241121

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241122

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241122

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250411

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251006

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260203

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260211